Topic: Lynparza Approved To Treat High-Risk, Early-Stage, HER2-, BRCA+

Forum: Genetic Testing — ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53, and mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM)

Posted on: May 10, 2022 02:53PM

Posted on: May 10, 2022 02:53PM

moderators wrote:

Lynparza Approved To Treat High-Risk, Early-Stage, HER2-Negative Breast Cancer With BRCA Mutation
Mar 13, 2022

The FDA approved Lynparza to treat early-stage, HER2-negative breast cancer with a BRCA1 or BRCA2 mutation and a high risk of recurrence, which also has been previously treated with chemotherapy — either before or after surgery. Read more...

To send a PM to the Mods: community.breastcancer.org/my/...
Log in to post a reply
Scroll to top button